Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by PDMitchellon Apr 18, 2012 9:40am
240 Views
Post# 19806634

RE: FDA requires more info before

RE: FDA requires more info before

Strange.  Pliaglis was approved by the U.S. Food and Drug Administration (FDA) in June 2006 and was voluntarily removed from the U.S. market in 2008, due to manufacturing issues at Galderma’s contract manufacturer. 

Surely the supplemental New Drug Application for Pliaglis concerned the new plant rather than approval per se.  What additional info might the FDA Want?

 

Sisyphus and Nuvo have much in common!

 

Bullboard Posts